By overcoming resistance associated with BCL‐2 inhibitors, this dual‐targeting approach provides a precise and potent therapeutic strategy, minimizing off‐target toxicity and enhancing treatment efficacy in AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.